Literature DB >> 35312466

Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy.

Shelsey W Johnson1,2,3, Kari R Gillmeyer1,2,3, Rendelle E Bolton1,4, Megan B McCullough1,5, Shirley X Qian1, Bradley A Maron2,6, Elizabeth S Klings3, Renda Soylemez Wiener1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35312466      PMCID： PMC9278628          DOI： 10.1513/AnnalsATS.202110-1168RL

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  14 in total

1.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Respir J       Date:  2015-08-29       Impact factor: 16.671

2.  Achieving integration in mixed methods designs-principles and practices.

Authors:  Michael D Fetters; Leslie A Curry; John W Creswell
Journal:  Health Serv Res       Date:  2013-10-23       Impact factor: 3.402

3.  Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns.

Authors:  Omar A Minai; Steven D Nathan; Nicholas S Hill; David B Badesch; James K Stoller
Journal:  Respir Med       Date:  2010-01-21       Impact factor: 3.415

4.  A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine.

Authors:  Bradley A Maron; John J Ryan
Journal:  Circulation       Date:  2019-04-16       Impact factor: 29.690

5.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

6.  Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.

Authors:  Aaron Waxman; Ricardo Restrepo-Jaramillo; Thenappan Thenappan; Ashwin Ravichandran; Peter Engel; Abubakr Bajwa; Roblee Allen; Jeremy Feldman; Rahul Argula; Peter Smith; Kristan Rollins; Chunqin Deng; Leigh Peterson; Heidi Bell; Victor Tapson; Steven D Nathan
Journal:  N Engl J Med       Date:  2021-01-13       Impact factor: 91.245

7.  The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups.

Authors:  Henning Gall; Janine F Felix; Franziska K Schneck; Katrin Milger; Natascha Sommer; Robert Voswinckel; Oscar H Franco; Albert Hofman; Ralph T Schermuly; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Hossein A Ghofrani
Journal:  J Heart Lung Transplant       Date:  2017-02-17       Impact factor: 10.247

8.  Phosphodiesterase-5 Inhibitor Therapy for Pulmonary Hypertension in the United States. Actual versus Recommended Use.

Authors:  Deborah Kim; Kyung Min Lee; Marc R Freiman; W Ryan Powell; Elizabeth S Klings; Seppo T Rinne; Donald R Miller; Adam J Rose; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2018-06

9.  Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis.

Authors:  Kurt W Prins; Sue Duval; Jeremy Markowitz; Marc Pritzker; Thenappan Thenappan
Journal:  Pulm Circ       Date:  2017-03-24       Impact factor: 3.017

10.  Pulmonary hypertension in chronic lung disease and hypoxia.

Authors:  Steven D Nathan; Joan A Barbera; Sean P Gaine; Sergio Harari; Fernando J Martinez; Horst Olschewski; Karen M Olsson; Andrew J Peacock; Joanna Pepke-Zaba; Steeve Provencher; Norbert Weissmann; Werner Seeger
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.